Skip to main content
. 2021 Dec 8;13(3):380–385. doi: 10.1111/1759-7714.14266

FIGURE 2.

FIGURE 2

Overall survival of patients harboring BRAF, ERBB2, MET, RET, or ROS1 who were treated with palliative first‐line platinum‐based chemotherapy. The median OS was not reached in patients with ROS1 mutations. In patients with BRAF, ERBB2, MET, and RET mutations, median OS was 14.1, 34.5, 22.7, and 29.8 months, respectively (p = 0.006). OS, overall survival